| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615897 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 9 Pages |
Abstract
Overall, the increased use of ruxolitinib appears to have come predominantly at the expense of thalidomide and ESAs, while not having a large effect on the first-line use of hydroxyurea.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Andrew T. Kuykendall, Chetasi Talati, Najla Al Ali, Kendra Sweet, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji,